UROGEN PHARMA LTD
NASDAQ: URGN (UroGen Pharma Ltd.)
Last update: 5 hours ago11.51
0.10 (0.88%)
| Previous Close | 11.41 |
| Open | 11.49 |
| Volume | 475,854 |
| Avg. Volume (3M) | 491,275 |
| Market Cap | 530,546,560 |
| Price / Sales | 5.10 |
| Price / Book | 19.27 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2025 |
| Profit Margin | -140.35% |
| Operating Margin (TTM) | -108.11% |
| Diluted EPS (TTM) | -2.96 |
| Quarterly Revenue Growth (YOY) | 4.40% |
| Total Debt/Equity (MRQ) | 481.07% |
| Current Ratio (MRQ) | 6.01 |
| Operating Cash Flow (TTM) | -96.77 M |
| Levered Free Cash Flow (TTM) | -46.83 M |
| Return on Assets (TTM) | -25.78% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | UroGen Pharma Ltd. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 5.0 |
| Average | 2.38 |
|
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 8.40% |
| % Held by Institutions | 86.98% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 55.00 (HC Wainwright & Co., 377.85%) | Buy |
| Median | 25.00 (117.20%) | |
| Low | 16.00 (Goldman Sachs, 39.01%) | Hold |
| Average | 30.00 (160.64%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 10.68 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 28 Apr 2025 | 25.00 (117.20%) | Buy | 11.26 |
| 13 Mar 2025 | 25.00 (117.20%) | Buy | 10.90 | |
| HC Wainwright & Co. | 28 Apr 2025 | 55.00 (377.85%) | Buy | 11.26 |
| 11 Mar 2025 | 55.00 (377.85%) | Buy | 10.82 | |
| Goldman Sachs | 17 Apr 2025 | 16.00 (39.01%) | Hold | 9.67 |
| Scotiabank | 16 Apr 2025 | 23.00 (99.83%) | Buy | 10.39 |
| Ladenburg Thalmann | 19 Feb 2025 | 31.00 (169.33%) | Buy | 10.82 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |